Point72 Asset Management
PCRX icon

Point72 Asset Management’s Pacira BioSciences PCRX Stock Holding History

Point72 Asset Management’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-1,075,673
Closed -$20.3M – 2420
2024
Q4 		$20.3M Buy
+1,075,673
New +$18.9M 0.04% 445
2023
Q4 		– Sell
-1,032
Closed -$31.7K – 2658
2023
Q3 		$31.7K Buy
1,032
+612
+146% +$22.1K ﹤0.01% 2210
2023
Q2 		$16.8K Sell
420
-478,796
-100% -$19.8M ﹤0.01% 1822
2023
Q1 		$19.6M Buy
+479,216
New +$19.1M 0.06% 356
2020
Q1 		– Sell
-30,744
Closed -$1.39M – 1009
2019
Q4 		$1.39M Sell
30,744
-300,035
-91% -$12.7M 0.01% 669
2019
Q3 		$12.6M Sell
330,779
-833,862
-72% -$33.3M 0.08% 304
2019
Q2 		$50.6M Buy
1,164,641
+531,059
+84% +$22.5M 0.27% 97
2019
Q1 		$24.1M Buy
633,582
+24,017
+4% +$937K 0.11% 212
2018
Q4 		$26.2M Buy
609,565
+371,169
+156% +$17.3M 0.13% 206
2018
Q3 		$11.7M Buy
238,396
+136,760
+135% +$5.91M 0.05% 434
2018
Q2 		$3.26M Buy
101,636
+89,936
+769% +$3.1M 0.01% 695
2018
Q1 		$364K Sell
11,700
-489,300
-98% -$17.4M ﹤0.01% 864
2017
Q4 		$22.9M Sell
501,000
-583,886
-54% -$23.1M 0.1% 276
2017
Q3 		$40.7M Buy
1,084,886
+914,686
+537% +$36.8M 0.18% 150
2017
Q2 		$8.12M Buy
170,200
+100,200
+143% +$4.65M 0.05% 430
2017
Q1 		$3.19M Buy
+70,000
New +$3.03M 0.02% 609
2016
Q3 		– Sell
-281,236
Closed -$9.49M – 824
2016
Q2 		$9.49M Buy
+281,236
New +$13.8M 0.06% 308

Other funds holding PCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DPCM
Doma Perpetual Capital Management Miami, Florida $372M AUM 14.96% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Point72 Asset Management's PCRX Position: Q1 2025 in Review

Point72 Asset Management sold out of Pacira BioSciences (PCRX) in Q1 2025, closing a stake of 1,075,673 shares — an estimated $20.3M sold.

Point72 Asset Management first reported a position in PCRX in Q2 2016 and held it in 17 quarters. The position peaked at $50.6M in Q2 2019. 235 funds tracked by Wall St. Rank hold PCRX as of Q1 2025.

  • Point72 Asset Management reported no remaining Pacira BioSciences position as of Q1 2025 after selling out during the quarter.
  • Point72 Asset Management sold 1,075,673 Pacira BioSciences shares in Q1 2025, an estimated $20.3M.
  • Point72 Asset Management first reported a position in Pacira BioSciences in Q2 2016 and held it in 17 quarters.
  • Point72 Asset Management's Pacira BioSciences position peaked at $50.6M in Q2 2019.
  • 235 funds tracked by Wall St. Rank held Pacira BioSciences as of Q1 2025.

Based on Point72 Asset Management's 13F filing for Q1 2025, filed 15 May 2025.